Enhancing Anti-Tumor Immunity by Combining KRAS inhibition with Immune Checkpoint Blockade to Improve Treatment Responses
- Overcoming the immunosuppressive tumor microenvironment (TME) of KRAS-mutant tumors
- Improving understanding of the influence KRAS inhibition on tumor immune responses to increase effectiveness of immune therapies
- Exploring combination strategies to overcome challenges posed by the TME and tumor stroma